ATE476178T1 - Hemmung der t-lymphozyten-aktivierung durch 3- deoxyflavonoide und relevante therapien - Google Patents

Hemmung der t-lymphozyten-aktivierung durch 3- deoxyflavonoide und relevante therapien

Info

Publication number
ATE476178T1
ATE476178T1 AT02798140T AT02798140T ATE476178T1 AT E476178 T1 ATE476178 T1 AT E476178T1 AT 02798140 T AT02798140 T AT 02798140T AT 02798140 T AT02798140 T AT 02798140T AT E476178 T1 ATE476178 T1 AT E476178T1
Authority
AT
Austria
Prior art keywords
compounds
rutin
deoxyflavonoids
inhibition
lymphocyte activation
Prior art date
Application number
AT02798140T
Other languages
English (en)
Inventor
Thomas Lahey
V Rajadhyaksha
Original Assignee
Synorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synorx Inc filed Critical Synorx Inc
Application granted granted Critical
Publication of ATE476178T1 publication Critical patent/ATE476178T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT02798140T 2001-09-06 2002-09-06 Hemmung der t-lymphozyten-aktivierung durch 3- deoxyflavonoide und relevante therapien ATE476178T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31766601P 2001-09-06 2001-09-06
US40712502P 2002-08-30 2002-08-30
PCT/US2002/028348 WO2003022994A2 (en) 2001-09-06 2002-09-06 Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto

Publications (1)

Publication Number Publication Date
ATE476178T1 true ATE476178T1 (de) 2010-08-15

Family

ID=26981074

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02798140T ATE476178T1 (de) 2001-09-06 2002-09-06 Hemmung der t-lymphozyten-aktivierung durch 3- deoxyflavonoide und relevante therapien

Country Status (11)

Country Link
US (2) US6774142B2 (de)
EP (1) EP1429750B1 (de)
JP (1) JP2005504796A (de)
KR (1) KR20040048407A (de)
CN (1) CN1668287B (de)
AT (1) ATE476178T1 (de)
AU (1) AU2002332878A1 (de)
BR (1) BR0212354A (de)
DE (1) DE60237213D1 (de)
MX (1) MXPA04002077A (de)
WO (1) WO2003022994A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102386A1 (en) * 2001-09-06 2004-05-27 Thomas Lahey Inhibition by 3-deoxyflavonoids of T-lymphocyte activation and therapies related thereto
DE10359384A1 (de) * 2003-12-18 2005-07-28 Anoxymer Gmbh Verwendung eines Extraktes von Aloysia triphylla als Matrixprotektor
CA2572815A1 (en) * 2004-07-09 2006-01-19 Medicure International Inc. Combination therapies employing nicotinic acid derivatives or fibric acid derivatives
WO2006030322A2 (en) * 2004-09-17 2006-03-23 University Of Manitoba Use of fla vone/fla vanone derivatives fn the treatment or prevention of respiratory conditions
NZ560633A (en) * 2005-03-11 2011-08-26 Neuprotect Pty Ltd Flavonoid compounds and uses thereof
CN101171026A (zh) * 2005-05-06 2008-04-30 阿明诺化学株式会社 软骨代谢异常疾病改善用健康食品及药品组合物
WO2007057767A2 (en) * 2005-11-17 2007-05-24 Pfizer Limited Amino acid derivatives
KR100817662B1 (ko) 2006-03-23 2008-03-27 주식회사 엘지생활건강 ｃ-Ｋｉｔ 활성 저해제, 피부미백제 및 이를 함유하는피부미백용 조성물
WO2007087442A2 (en) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
CA2640090A1 (en) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
US20090258939A1 (en) * 2007-07-31 2009-10-15 Wendye Robbins Pyrone analog compositions and methods
CA2693338A1 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
GB0805312D0 (en) * 2008-03-20 2008-04-30 Medical Res Council Modulation of the immune response
EP2334296A4 (de) * 2008-08-29 2012-04-25 Novogen Res Pty Ltd Immunmodulierende aktivitäten
CA2740003A1 (en) * 2008-10-10 2010-04-15 Limerick Biopharma, Inc. Pyrone analogs for therapeutic treatment
EP2424541A2 (de) * 2009-04-27 2012-03-07 Limerick BioPharma, Inc. Phosphorylierte und phosphonierte pyron-analoga zur therapeutischen behandlung
JP5594719B2 (ja) * 2010-01-06 2014-09-24 国立大学法人神戸大学 筋肉の糖取り込み促進剤
CA2816322A1 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compositions and methods for the treatment of cancer
CA2844670A1 (en) 2011-08-12 2013-02-21 Salk Institute For Biological Studies Neuroprotective polyphenol analogs
CN102872155B (zh) * 2012-10-30 2014-04-02 中国人民解放军第四军医大学 一种黄酮苷类化合物在制备治疗脑中风药物中的应用
KR101497935B1 (ko) * 2013-04-19 2015-03-03 경북대학교 산학협력단 루테올린을 유효성분으로 포함하는 섬유증의 예방 또는 치료용 조성물
EP2894200A1 (de) * 2014-01-13 2015-07-15 Rubia Exploitatie B.V. Verfahren zur Herstellung einer Farbstoffpräparation
CN104387360B (zh) * 2014-11-21 2016-10-05 潍坊医学院 柚皮素脂肪酸酯、其制备方法和以该化合物为活性成分的药物组合物及其应用
CN107427003B (zh) 2015-02-02 2023-01-31 梅制药公司 联合治疗
JP6785796B2 (ja) * 2015-05-21 2020-11-18 オフタルミ モナコＯｐｈｔａｌｍｉｓ Ｍｏｎａｃｏ 浸透圧保護剤としてのリポ酸およびタウリンの組み合わせ
CN108395461B (zh) * 2017-02-07 2022-01-07 浙江康恩贝制药股份有限公司 7,4′-O-β-D-葡萄糖桑色素苷及其制备和其在制备抗炎药物中的应用
GB201811312D0 (en) * 2018-07-10 2018-08-29 Nuchido Ltd Compositions
CN109265424B (zh) * 2018-09-25 2020-08-21 天津中医药大学 一种黄酮类衍生物及其制备方法和鉴定方法
JP2022514470A (ja) * 2018-12-14 2022-02-14 エフ．ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を治療および予防するためのクロマン－４－オン誘導体
CN109620771B (zh) * 2018-12-19 2022-08-26 浙江奥比特生物科技有限公司 一种肌肤抗炎祛痘的化妆品组合物及其产品
CN110642825B (zh) * 2019-10-16 2021-06-15 中国海洋大学 一种黄酮类衍生物及其制备方法和在制备免疫增强剂中的应用
CN111978330B (zh) * 2020-09-03 2023-08-22 中国科学院昆明植物研究所 黄烷醇-脂肪醇杂合体及其药物组合物与其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867541A (en) * 1972-05-03 1975-02-18 Ralph C Robbins Compositions and methods for disaggregating blood cells
JPS5899414A (ja) * 1981-12-10 1983-06-13 Jun Okuda アルド−スレダクタ−ゼの阻害剤
JP2544734B2 (ja) * 1987-03-24 1996-10-16 コスモ開発株式会社 免疫抑制剤
JPH03232851A (ja) * 1989-12-26 1991-10-16 Nippon Flour Mills Co Ltd アルドース還元酵素阻害剤
JPH05286962A (ja) * 1992-02-14 1993-11-02 Kyowa Hakko Kogyo Co Ltd ５−アミノフラボン誘導体
JPH08104628A (ja) * 1994-10-04 1996-04-23 Sumitomo Pharmaceut Co Ltd マトリックスメタロプロテアーゼ阻害剤
AU4547496A (en) * 1995-02-06 1996-08-27 Kyowa Hakko Kogyo Co. Ltd. 5-aminoflavone derivatives
JPH09176010A (ja) * 1995-12-27 1997-07-08 Kureha Chem Ind Co Ltd Ｈｓｐ６０ファミリーに属するタンパク質のフラボノイド含有合成抑制剤
JPH09176011A (ja) * 1995-12-27 1997-07-08 Kureha Chem Ind Co Ltd Ｈｓｐ２７ファミリーに属するタンパク質のフラボノイド含有合成抑制剤
US6506792B1 (en) 1997-03-04 2003-01-14 Sterix Limited Compounds that inhibit oestrone sulphatase and/or aromatase and methods for making and using
AU2225597A (en) * 1996-03-05 1997-09-22 Imperial College Of Science, Technology And Medicine Compounds with a sulfamate group
KR20010071836A (ko) * 1998-09-01 2001-07-31 성재갑 플라본 구조를 갖는 신규한 사이클린 의존 키나아제 저해제
KR20000019716A (ko) * 1998-09-15 2000-04-15 박호군 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
CA2368215A1 (en) * 1999-04-05 2000-10-12 Randy H. Ziegler Compositions and methods for treatment of diabetes
WO2001021608A2 (en) * 1999-09-23 2001-03-29 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Novel flavonoids
US6334998B1 (en) * 1999-12-07 2002-01-01 Parker Hughes Institute Estrogens for treating ALS
EP1127572A3 (de) * 2000-02-25 2003-05-02 Basf Aktiengesellschaft Verwendung von Flavonen zur Behandlung von Cyclooxygenase-2 ermittelten Krankheiten
JP2002010753A (ja) * 2000-04-24 2002-01-15 Marukin Chuyu Co Ltd オリーブ葉またはその抽出成分を含有するアミラーゼ阻害剤および高血糖者用食品

Also Published As

Publication number Publication date
US20030069192A1 (en) 2003-04-10
JP2005504796A (ja) 2005-02-17
EP1429750B1 (de) 2010-08-04
CN1668287A (zh) 2005-09-14
BR0212354A (pt) 2004-11-30
WO2003022994A2 (en) 2003-03-20
CN1668287B (zh) 2012-03-28
US20040209825A1 (en) 2004-10-21
EP1429750A2 (de) 2004-06-23
WO2003022994A3 (en) 2003-10-09
US6774142B2 (en) 2004-08-10
KR20040048407A (ko) 2004-06-09
MXPA04002077A (es) 2005-02-17
DE60237213D1 (de) 2010-09-16
EP1429750A4 (de) 2005-08-03
AU2002332878A1 (en) 2003-03-24

Similar Documents

Publication Publication Date Title
DE60237213D1 (de) Hemmung der t-lymphozyten-aktivierung durch 3-deoxyflavonoide und relevante therapien
TW200612934A (en) Quaternary salt CCR2 antagonists
SG91925A1 (en) Post treatment of via opening by n-containing plasma or h-containing plasma for elimination of fluorine species in the fsg near the surfaces of the via opening
CY1110114T1 (el) Προσδετης αλφα-2-δελτα για την αγωγη των συμπτωματων του κατωτερου ουροποιητικου συστηματος
GB0322266D0 (en) Alternate path multilateral production/injection
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
DE60327883D1 (de) Analgetische verwendung von (s)-norketamin
MXPA04010625A (es) Antagonista de receptor de taquicinina.
NO20062300L (no) Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser
NO20052169L (no) Dihydropyridinforbindelser med samtidig evne til a blokkere L-type kalsiumkanaler og a inhibere fosfodiesterase type 3 aktivitet
ATE478863T1 (de) Heterotetracyclische verbindungen als tpo- mimetica
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
WO2007005625A3 (en) Systems and methods for synchronizing music
ATE295928T1 (de) Gleitschienentürschliesser
NO20064880L (no) behandling av nevrologiske tilstander ved anvendelse av komplement C5a-reseptormodulatorer
DE602005003404D1 (de) Brechhammer und Befestigungselement, Seitenplatte und Schutzgehäuse des Brechhammers
TNSN05197A1 (en) Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation -and immunologically- mediated diseases
EA200100930A1 (ru) Способ лечения хозл
EP1736472A4 (de) 2-aminopyridinderivat
GB0219801D0 (en) Post guard
TR200402036T4 (tr) (-)-Cis-2-(2-Klorofenil)-5, 7-Dihidroksi-8-[4R-(3S-Hidroksi-1-Metil) Piperidinil]-4H-1- Benzopiran-4-on'un psödopolimorfu
IL179105A0 (en) Butyrylcholinesterase selective inhibitors
ES1054619U (es) Barrera de proteccion
ITMI20021645A1 (it) Buratto piano con dispositivo di campionamento a sicurezza migliorata
ITTO20020065U1 (it) Recinzione modulare anti-intrusione.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties